Bio-Rad Laboratories Files 8-K on Financials
Ticker: BIO-B · Form: 8-K · Filed: Oct 30, 2024 · CIK: 12208
| Field | Detail |
|---|---|
| Company | Bio-Rad Laboratories, Inc. (BIO-B) |
| Form Type | 8-K |
| Filed Date | Oct 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
BIO-RAD files 8-K with financial results, check it out.
AI Summary
Bio-Rad Laboratories, Inc. filed an 8-K on October 30, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's performance.
Why It Matters
This filing provides investors with updated financial information and operational results for Bio-Rad Laboratories, Inc., crucial for assessing the company's current performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any unusual risks or significant negative events.
Key Players & Entities
- BIO-RAD LABORATORIES, INC. (company) — Registrant
- October 30, 2024 (date) — Date of Report
- 1000 Alfred Nobel Dr. Hercules , California 94547 (address) — Principal executive offices
- 5107247000 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Bio-Rad Laboratories, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on October 30, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 1000 Alfred Nobel Dr. Hercules, California 94547.
What is Bio-Rad Laboratories, Inc.'s telephone number?
Bio-Rad Laboratories, Inc.'s telephone number is (510) 724-7000.
What is the SIC code for Bio-Rad Laboratories, Inc.?
The Standard Industrial Classification (SIC) code for Bio-Rad Laboratories, Inc. is 3826, which corresponds to Laboratory Analytical Instruments.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-10-30 16:17:53
Key Financial Figures
- $0.0001 — stered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange
Filing Documents
- bio-20241030.htm (8-K) — 34KB
- bio-8k10302024xex991.htm (EX-99.1) — 419KB
- 0000012208-24-000062.txt ( ) — 641KB
- bio-20241030.xsd (EX-101.SCH) — 2KB
- bio-20241030_def.xml (EX-101.DEF) — 15KB
- bio-20241030_lab.xml (EX-101.LAB) — 27KB
- bio-20241030_pre.xml (EX-101.PRE) — 16KB
- bio-20241030_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
ITEM 2.02 Results of Operations and Financial Condition On October 30, 2024, Bio-Rad Laboratories, Inc. announced its financial results for the quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report. In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
ITEM 9.01 Financial Statements and Exhibits Exhibit Number Description 99.1 Press release of Bio-Rad Laboratories, Inc. dated October 30, 2024 104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-RAD LABORATORIES, INC. Date: October 30, 2024 By: /s/ Roop K. Lakkaraju Roop K. Lakkaraju Executive Vice President and Chief Financial Officer